Maple Leaf Green World Valuation

Is MGWF.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MGWF.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MGWF.F ($0.03) is trading below our estimate of fair value ($0.19)

Significantly Below Fair Value: MGWF.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MGWF.F?

Key metric: As MGWF.F is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MGWF.F. This is calculated by dividing MGWF.F's market cap by their current book value.
What is MGWF.F's PB Ratio?
PB Ratio	-0.2x
Book	-CA$9.96m
Market Cap	CA$1.25m

MGWF.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-21.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MGWF.F's PB Ratio compare to its peers?

The above table shows the PB ratio for MGWF.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.2x
TFFP TFF Pharmaceuticals	0.5x	n/a	US$1.5m
SPRC SciSparc	0.1x	63.0%	US$768.3k
SXTC China SXT Pharmaceuticals	0.1x	n/a	US$1.4m
CYTO Altamira Therapeutics	0.2x	-5.9%	US$1.5m
MGWF.F Maple Leaf Green World	n/a	n/a	US$892.2k

Price-To-Book vs Peers: MGWF.F has negative equity and a Price-To-Book Ratio (-0.2x) compared to the peer average (0.2x).

Price to Book Ratio vs Industry

How does MGWF.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 Companies	Price / Book	Estimated Growth	Market Cap
CTXR Citius Pharmaceuticals	0.3x	55.3%	US$25.65m
SHWZ Medicine Man Technologies	0.09x	n/a	US$8.02m
TNFA TNF Pharmaceuticals	0.2x	n/a	US$3.11m
UPC Universe Pharmaceuticals	0.1x	n/a	US$2.81m

24 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: MGWF.F has negative equity and a Price-To-Book Ratio (-0.2x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is MGWF.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MGWF.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MGWF.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.23

0.6%

13.2%

Collegium Pharmaceutical

US$983.6m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.50

1.8%

19.1%

Teva Pharmaceutical Industries

US$19.0b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.78

-2.0%

72.8%